Glick H, Heyse J F, Thompson D, Epstein R S, Smith M E, Oster G
University of Pennsylvania.
Int J Technol Assess Health Care. 1992 Fall;8(4):719-34. doi: 10.1017/s0266462300002403.
We describe and illustrate the use of a generalizable model for evaluating the cost-effectiveness of alternative cholesterol-lowering treatments. We combine standard incidence-based techniques for measuring the cost of illness with logistic risk functions from the Framingham Heart Study to project, for persons with known coronary risk characteristics, the likelihood of developing coronary heart disease (CHD) over a lifetime as well as a number of related outcomes, including the expected loss of years of life due to CHD, the expected lifetime direct and indirect costs of CHD, and the changes in these outcomes that would result from cholesterol-lowering treatment.
我们描述并举例说明了一种可推广模型的应用，该模型用于评估替代降胆固醇治疗的成本效益。我们将基于发病率的标准技术用于衡量疾病成本，并结合弗雷明汉心脏研究的逻辑风险函数，来预测具有已知冠心病风险特征的人群一生中患冠心病（CHD）的可能性以及一些相关结果，包括因冠心病导致的预期寿命损失年数、冠心病的预期终身直接和间接成本，以及降胆固醇治疗将导致的这些结果的变化。
